Ignite Creation Date:
2025-12-24 @ 4:03 PM
Ignite Modification Date:
2026-01-04 @ 3:57 PM
Study NCT ID:
NCT04609566
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-12-15
First Post:
2020-10-23
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors
Sponsor:
Seagen, a wholly owned subsidiary of Pfizer
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
SGN35-033
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |